Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Innate Immuno’s MS trial drug gets global spotlight

For Immediate Release

Innate Immuno’s MS trial drug gets global spotlight

Auckland, NZ, October 12 2012: Research details of a drug that may help people with secondary multiple sclerosis (MS), developed by New Zealand biopharmaceutical company Innate Immunotherapeutics, is being highlighted at the world’s biggest annual gathering of MS specialists and pharmaceutical companies, ECTRIMS, in Lyon, France today.

Innate’s study co-principal investigator, Dr Alison Luckey, talk about the result of 1B/2A trials of its drug MIS416 in the late breaking news section of ECTRIMS. More than 6,000 people attend the conference.

Simon Wilkinson, chief executive of Innate Immunotherapeutics, says results of the Phase 1/2 clinical trial have shown MIS416 to be well tolerated and identified a clinical dose for further evaluation.

“For most international clinicians and researchers into MS this will be the first time they will heard about our drug, that it has been in early stage trials and most importantly that early results are encouraging,” he says. “We are grateful for the support of the United States National MS Society at ECTRIMS, especially for the credibility and validation of our programme the society’s support provides.”

Neurologist Professor Tim Anderson, co-principal investigator for the study, announced in June this year that preliminary data indicate MIS416 is safe and well tolerated. The MS-related clinical status assessment tools used during the study also indicate that the trial agent may have had some positive effect for many of the treated patients.

During the dose confirmation portion of the study, eight of 10 patients with secondary progressive MS treated with MIS416 for 12 weeks showed some improvement in their MS-related signs and symptoms.

Innate Immunotherapeutics plans to enroll MS suffers in 2013 for a 12 month Phase 2B study to investigate the sustainability of the improvements in seen in the first study.

“We plan to conduct most of the next study in Australia, to take advantage of that country’s greater patient availability,” Mr Wilkinson says. “If we can get appropriate local support it would be good to also have trial sites in New Zealand too. Right now we are working hard during the next few months to raise around US$10 million that we need to run that longer phase 2B study. We are certainly hopeful our exposure at ECTRIMS will help us with that.”

In addition to the support of the United States-based National Multiple Sclerosis Society, Innate has had financial support from the New Zealand Ministry of Science and Innovation. It is also collaborating with New Zealand and US universities that specialise in oncology research, to conduct preclinical studies of MIS416 in other applications, including treatment vaccines for a number of different cancers.

Ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Sky City : Auckland Convention Centre Cost Jumps By A Fifth

SkyCity Entertainment Group, the casino and hotel operator, is in talks with the government on how to fund the increased cost of as much as $130 million to build an international convention centre in downtown Auckland, with further gambling concessions ruled out. The Auckland-based company has increased its estimate to build the centre to between $470 million and $530 million as the construction boom across the country drives up building costs and design changes add to the bill.
More>>

ALSO:

RMTU: Mediation Between Lyttelton Port And Union Fails

The Rail and Maritime Union (RMTU) has opted to continue its overtime ban indefinitely after mediation with the Lyttelton Port of Christchurch (LPC) failed to progress collective bargaining. More>>

Earlier:

Science Policy: Callaghan, NSC Funding Knocked In Submissions

Callaghan Innovation, which was last year allocated a budget of $566 million over four years to dish out research and development grants, and the National Science Challenges attracted criticism in submissions on the government’s draft national statement of science investment, with science funding largely seen as too fragmented. More>>

ALSO:

Scoop Business: Spark, Voda And Telstra To Lay New Trans-Tasman Cable

Spark New Zealand and Vodafone, New Zealand’s two dominant telecommunications providers, in partnership with Australian provider Telstra, will spend US$70 million building a trans-Tasman submarine cable to bolster broadband traffic between the neighbouring countries and the rest of the world. More>>

ALSO:

More:

Statistics: Current Account Deficit Widens

New Zealand's annual current account deficit was $6.1 billion (2.6 percent of GDP) for the year ended September 2014. This compares with a deficit of $5.8 billion (2.5 percent of GDP) for the year ended June 2014. More>>

ALSO:

Still In The Red: NZ Govt Shunts Out Surplus To 2016

The New Zealand government has pushed out its targeted return to surplus for a year as falling dairy prices and a low inflation environment has kept a lid on its rising tax take, but is still dangling a possible tax cut in 2017, the next election year and promising to try and achieve the surplus pledge on which it campaigned for election in September. More>>

ALSO:

Job Insecurity: Time For Jobs That Count In The Meat Industry

“Meat Workers face it all”, says Graham Cooke, Meat Workers Union National Secretary. “Seasonal work, dangerous jobs, casual and zero hours contracts, and increasing pressure on workers to join non-union individual agreements. More>>

ALSO:

Get More From Scoop

 
 
Standards New Zealand

Standards New Zealand
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news